Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240044/S007

Globe Catheter and Globe Pulsed Field System

Kardium, Inc. · Decision date Oct 27, 2026

MEDTECHLEDGER EXPLANATIONP240044/S007

What did the FDA approve?

FDA lists PMA supplement P240044/S007 for Kardium, Inc.'s Globe® Catheter and Globe® Pulsed Field System as approved on 2026-10-27. The supplement is classified as a Real-Time Process change for design/components/specifications/material. The S007 suffix ties the record to the original P240044 approval rather than constituting a separate approval of the complete system.

The reported purpose is an update to the flexible circuits of the Globe® Catheter array, which uses irreversible electroporation for atrial fibrillation ablation in the cardiovascular category under product code QZI. Beyond this field-level description, the database entry does not disclose the prior circuit design, the nature of the change, test methods, or performance results, and it does not present independent proof of safety or clinical effectiveness; the approval status is the agency's decision on the manufacturing change as described.

FDA approval order statement

approval for update to the flexible circuits of the Globe Catheter array
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 27, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240044/S007
Regulatory pathway
PMA supplement
Applicant
Kardium, Inc.
Product code
QZI
Decision code
APPR
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation.

Applicant
Kardium, Inc.
Product code
QZI
FDA device class
3

For the original device and its historical approval scope, see PMA P240044. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240044 · Original PMA

    Globe Pulsed Field System

  2. P240044/S007 received

    Application receipt date recorded by FDA.

  3. P240044/S008 · Related supplement

    Globe Pulsed Field System; Globe Catheter

  4. P240044/S007 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P240044. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240044

Product / regulatory recordCompanyPathwayDecision dateSource
Kardium, Inc.PMA approvalAug 27, 2025FDA
Kardium, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code QZI

Product / regulatory recordCompanyPathwayDecision dateSource
Biosense Webster, Inc.PMA supplementNov 3, 2026FDA
Volt PFA SystemP250022/S002
ABBOTT MEDICALPMA supplementOct 15, 2026FDA
Medtronic, Inc.PMA supplementOct 9, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA
ABBOTT MEDICALPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Kardium, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
8518 Glenlyon Pkwy., Unit 155, Burnaby, V5J OB6

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records